The use of GSIs that were originally developed for Alzheimer’s disease and cancer is primarily based on the premise that GSIs act by inhibiting the cleavage of GS on Notch ligands, thereby resulting in Notch 1 signaling blockade [34–38]. Here, NOTCH1 is linked to early-onset autosomal dominant Alzheimer disease.